Research Center Profile:
Cardiology/Vascular Diseases
The Mexican Institute of Clinical Research is an institution
fully dedicated to conduct clinical research in Mexico covering
most therapeutic areas, with an affiliation with major medical
centers from the public and private sector. We are served by
central IRB that independently meet every other week to review and
approve submitted protocols. IMIC also provide the service of
protocol submission before the local Ministry of Health in order to
conduct the trial in Mexico under the local legislations.
IMIC clinical research activities are performed under the strict
guidelines of the GCP-ICH, local regulations and sponsor
directives. We have created an infrastructure in order to observe
these guidelines by establishing dedicated supporting groups that
will assist the study teams and the protocol to be in compliance.
The dedicated groups are Telemarketing department that assist the
investigators design subject recruitment strategies; Project
Management to assist in the planning of the study logistics;
Quality Assurance that under the quality control process assist the
research teams be in compliance. In addition IMIC has a pharmacy
and laboratory that helps maintain the control of the study drug
inventories and perform the study specimen collection procedures
respectively.
IMIC has been in operations since March of 2000 conducting
clinical research from Phase I - IV. IMIC has full time trained
study coordinators with background in medical science form
physicians, biologist, psychologists, and nutritionist. All study
personnel are trained under the regulatory discipline of the ICH,
GCP and local regulations.
Our experience is based on the following areas:
Cardiology
Hypertension
Cardiovascular
Essential Hypertension
Moderate Hypertension
Congestive Heart Failure (NYHU Class11/111)
Dental
Dermatology
Dry Skin
Atopic Dermatitis
Atopic Dermatitis (Pediatric)
Psoriasis
Onycomycosis
Neurofibromatosis
Atopic Dermatitis (Pediatric)
Endocrinology
Diabetes
Diabetes (Naive)
Diabetes (Pediatric)
Diabetes (Inhaled Insulin)
Diabetes (Type 2 - Inhaled Insulin)
Diabetes (Type 1 & 2 - Inhaled Insulin)
Diabetic (Neuropathy)
Diabetes (Type 2 - tx with Metformin)
ENT (Ear, Nose & Throat)
Gastroenterology
Clostridium Dificile
Irritable Bowel Syndrome
Bariatric Surgical Device
Ulcerative Colitis
Hematology
Iron Deficiency Anemia (Secondary to heavy Uterine
Bleeding)
Iron Deficiency Anemia (In non-dialysis dependent pediatric
patients)
Immunology-Infectious Diseases
HIV/AIDS (Pediatric)
Vaccine
Vaccine (Rotavirus)
Nephrology-Urology
Prostatic Hyperplasia
Urinary Retention
Parkinson Disease
Peritoneal Dialysis
Neurology-CNS
Panic Disorder
Depression
Anxiety
Major Depression
Nutrition
Obstetrics-Gynecology
Papiloma Virus
Bacterial Vaginosis
BV-VV Candidacies Infection
Post Partum Anemia
Oncology
Prostate Cancer
Lung Cancer
Pancreatic Cancer
Breast Cancer
Ophthalmology
Glaucoma (Pediatric)
Glaucoma
Conjunctivitis
Keratoplasty
Macular Degeneration
Pulmonary
Asthma
Asthma (Pediatric)
Rheumatology
Osteoporosis
Osteoarthritis
Rheumatoid Arthritis
IMIC is located in Mexico City near the downtown area with easy
access to patients and visitors via subway or any other kind of
transportation. Our facility consists of 13,000 SF of space with 10
equipped medical offices, pharmacy, laboratory, central file, and
monitoring office that are integrated to facilitate the conduction
of the trial. IMIC has also integrated a computer and telephone
system that facilitate the communication with our clients and the
industry in cases such as IVRS for patient randomization and the
use of electronic CRF.
IMIC has among the investigators’ experience an investigator
network that allows us to select the investigator in any of the
therapeutic areas required for the conduction of the study either
in-house or with any of the affiliate medical institutions. The
network includes trained investigators within the private and or
public institutions where they are currently practice and where the
study is conducted.
Adolfo Dorenbaum, BSBA - Chief Executive Officer
Mr. Dorenbaum obtained his BSBA from Boston University, Boston, MA. He has spent many years as a consultant setting upnew business in Mexico City; with extensive experience in financial management. He has participated in the publicadministration privatization process, instrumental for the odernization of Mexican economy. At present, he is responsible forIMIC’s contracts and financial-related activities.
Gina Gorodezky, MD - Medical Director
Dr. Gorodezky obtained her Medical Doctor degree from the Universidad NacionalAutonoma de Mexico. Was trained at M.D.Anderson Research Cancer Center as a Hemato/oncologist. She has worked at the Cancer Institute in Mexico City and at theMexican Cardiology Institute. She has participated in multiple clinical research studies in Mexico, USA., United Kingdom andEuropean Union.
Marc D. Russo, MCSE - Business Development & Marketing / CTO
Mr. Russo is an experienced entrepreneur, with a background of business set-up, organization, and coordination in diversecommercial ambiences. He entered the Clinical Research environment through one of his areas of expertise, computerconsulting, and rapidly joined IMIC’s marketing andrepresentation area.
Jorge Luis Childres Flores, - Director of Quality Assurance
Dr. Childres Flores graduated from the National Polytechnic Institute in Mexico City. He previously worked in thepharmaceutical industry as a clinical monitor and products dossier registrations. Currently is the director of quality assuranceand is responsible for maintaining quality standards throughout all clinical trials conducted at IMIC.
Alissia Lomas - Director of Telemarketing
Ms. Lomas has a degree in Marketing from the Universidad Tecnologica de Mexico (UNITEC). She joined IMIC at the beginningof 2002 with long experience in developing marketing plans. Presently she is the responsible of the development andimplementation of patient recruitment strategies for most study protocols. Also, she manages the Central Call Center for IMICwhere all patients interested in participate in study protocols are registered.
Mexico City has a population of approximately 25 million people,
most under middle age and within one hour of our site or any of our
affiliated institutions. From our previous clinical research
experience, IMIC has created a patient database with more than
15,000 patients that have been recruited via news paper or
physician referrals.
All employees are 100% Bilingual, highly trained and fully
dedicated to clinical research.
Protocol are reviewed and approved by our local regulatory
agency within 45 to 65 days.
If you are interested in contacting this center to discuss placing a clinical
trial there, please complete and send the email form below. A representative from
the research center will then follow up with you.
